The Relative Strength (RS) Rating for Edwards Lifesciences stock jumped into a new percentile Tuesday, with a rise from 78 to 81.
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price performance over the last 52 weeks matches up against the rest of the market.
Decades of market research reveals that the best-performing stocks often have an RS Rating north of 80 as they begin their biggest climbs.
Risk Management In The Stock Market: How Much Money To Invest Now
Is Edward Lifesciences Stock A Buy?
Edwards Lifesciences stock is still within a buy range after moving past a 90.20 buy point in a cup with handle. Once a stock moves 5% or higher beyond the initial entry, it's considered out of a proper buying area.
Earnings grew 0% last quarter, up from -3% in the prior report. Revenue also increased, from 12% to 14%.
Edwards Lifesciences stock earns the No. 10 rank among its peers in the Medical-Products industry group. LifeMD, DexCom and Integer Holdings are among the top 5 highly rated stocks within the group.
